New medicines for treatment of COVID-19

Because the COVID-19 pandemic is a global health crisis of unprecedented magnitude, the European Medicines Agency (EMA) has intensified its processes in relation to COVID-19 medicines. This means that development, assessment and authorisation of both vaccines and other new medicines for treatment of people infected with COVID-19 can take place fast and efficiently without compromising the requirements for safety and scientific documentation.

Besides the COVID-19 vaccines, other medicines have been developed that can reduce the risk of spread and protect against severe illness related to COVID-19 (e.g. antiviral monoclonal antibodies and antiviral agents).

In step with gaining more knowledge about the disease caused by COVID-19, it has become possible to improve the treatment of patients who are ill with COVID-19 by using already authorised medicines and approved treatment methods.  

As with all other medicines on the market, the Danish Medicines Agency also monitors reported suspected side effects of medicines for treatment of COVID-19. The medicines are also monitored by the other EU countries and the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC).

New medicines for COVID-19 are developed and authorised on an ongoing basis. The EMA provides current updates on its website with details of medicines that have been authorised and new medicines being assessed.

You can read more about the individual medicines here: EMA's overview of medicines for COVID-19 treatment.